FDA declines expanded approval for Bristol-Myers' Opdivo drug

Published On 2015-11-28 04:26 GMT   |   Update On 2022-12-10 07:20 GMT
Advertisement
Bristol-Myers Squibb Co said the U.S. Food and Drug Administration declined to approve its immuno-oncology drug, Opdivo, for its expanded use to treat an additional type of advanced skin cancer.

Bristol-Myers said it received a so-called complete response letter from the health regulator, which indicated the need for additional data in the BRAF mutated patient population.

The regulator issues a complete response letter when a new or generic treatment cannot be approved in its current form.

The FDA approved Opdivo as a single agent for the treatment of patients with BRAF V600 wild-type melanoma earlier this week, but on Friday declined the approval of the drug for treating BRAF V600 mutation positive metastatic melanoma.

Opdivo, first approved in December 2014, raked in worldwide revenue of $467 million in the nine months ended Sept. 30.

The drug has been approved for five other indications in the past 12 months.

Metastatic melanoma is the least common skin cancer. It is also the most deadly because it spreads (metastasizes) quickly and easily to other parts of the body.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News